


# Amendment to the Claims

1. (Currently amended) A compounds of formula I:



I

wherein:

R<sup>1</sup> is selected from:

- 1) H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-6 cycloalkyl, and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
  - a) C<sub>1</sub>-6 alkyl,
  - b) C<sub>3</sub>-6 cycloalkyl,
  - c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
  - d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
  - e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
  - f) (F)<sub>p</sub>C<sub>1-3</sub> alkyl,
  - g) halogen,
  - h) OR<sup>4</sup>,
  - i) O(CH<sub>2</sub>)<sub>s</sub> OR<sup>4</sup>,
  - j) CO<sub>2</sub>R<sup>4</sup>,
  - k) (CO)NR<sup>10</sup>R<sup>11</sup>,
  - l) O(CO)NR<sup>10</sup>R<sup>11</sup>,

- m)  $N(R^4)(CO)NR^{10}R^{11}$ ,
- n)  $N(R^{10})(CO)R^{11}$ ,
- o)  $N(R^{10})(CO)OR^{11}$ ,
- p)  $SO_2NR^{10}R^{11}$ ,
- q)  $N(R^{10})SO_2R^{11}$ ,
- r)  $S(O)_mR^{10}$ ,
- s) CN,
- t)  $NR^{10}R^{11}$ ,
- u)  $N(R^{10})(CO)NR^4R^{11}$ , and
- v)  $O(CO)R^4$ ; and

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:

- a)  $C_{1-6}$  alkyl,
- b)  $C_{3-6}$  cycloalkyl,
- c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from  $R^4$ ,
- d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from  $R^4$ ,
- e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from  $R^4$ ,
- f)  $(F)_pC_{1-3}$  alkyl,
- g) halogen,
- h)  $OR^4$ ,
- i)  $O(CH_2)_sOR^4$ ,
- j)  $CO_2R^4$ ,
- k)  $(CO)NR^{10}R^{11}$ ,
- l)  $O(CO)NR^{10}R^{11}$ ,
- m)  $N(R^4)(CO)NR^{10}R^{11}$ ,
- n)  $N(R^{10})(CO)R^{11}$ ,
- o)  $N(R^{10})(CO)OR^{11}$ ,
- p)  $SO_2NR^{10}R^{11}$ ,
- q)  $N(R^{10})SO_2R^{11}$ ,

- r)  $S(O)_m R^{10}$ ,
- s) CN,
- t)  $NR^{10}R^{11}$ ,
- u)  $N(R^{10})(CO)NR^4R^{11}$ , and
- v)  $O(CO)R^4$ ; and

$R^2$  is independently selected from H and:

- 1)  $C_{1-6}$  alkyl,
- 2)  $C_{3-6}$  cycloalkyl,
- 3) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from  $R^4$ ,
- 4) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from  $R^4$ ,
- 5) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from  $R^4$ ,
- 6)  $(F)_p C_{1-3}$  alkyl,
- 7) halogen,
- 8)  $OR^4$ ,
- 9)  $O(CH_2)_5OR^4$ ,
- 10)  $CO_2R^4$ ,
- 11)  $(CO)NR^{10}R^{11}$ ,
- 12)  $O(CO)NR^{10}R^{11}$ ,
- 13)  $N(R^4)(CO)NR^{10}R^{11}$ ,
- 14)  $N(R^{10})(CO)R^{11}$ ,
- 15)  $N(R^{10})(CO)OR^{11}$ ,
- 16)  $SO_2NR^{10}R^{11}$ ,
- 17)  $N(R^{10})SO_2R^{11}$ ,
- 18)  $S(O)_m R^{10}$ ,
- 19) CN,
- 20)  $NR^{10}R^{11}$ ,
- 21)  $N(R^{10})(CO)NR^4R^{11}$ , and
- 22)  $O(CO)R^4$ ;

<sup>7</sup>  
R is selected from:

- 1) H, C<sub>0</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
  - a) C<sub>1</sub>-6 alkyl,
  - b) C<sub>3</sub>-6 cycloalkyl,
  - c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
  - d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
  - e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
  - f) (F)<sub>p</sub>C<sub>1-3</sub> alkyl,
  - g) halogen,
  - h) OR<sup>4</sup>,
  - i) O(CH<sub>2</sub>)<sub>s</sub>OR<sup>4</sup>,
  - j) CO<sub>2</sub>R<sup>4</sup>,
  - k) (CO)NR<sup>10</sup>R<sup>11</sup>,
  - l) O(CO)NR<sup>10</sup>R<sup>11</sup>,
  - m) N(R<sup>4</sup>)(CO)NR<sup>10</sup>R<sup>11</sup>,
  - n) N(R<sup>10</sup>)(CO)R<sup>11</sup>,
  - o) N(R<sup>10</sup>)(CO)OR<sup>11</sup>,
  - p) SO<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>,
  - q) N(R<sup>10</sup>) SO<sub>2</sub>R<sup>11</sup>,
  - r) S(O)<sub>m</sub>R<sup>10</sup>,
  - s) CN,
  - t) NR<sup>10</sup>R<sup>11</sup>,
  - u) N(R<sup>10</sup>)(CO)NR<sup>4</sup>R<sup>11</sup>,
  - v) O(CO)R<sup>4</sup>; and
- 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
  - a) C<sub>1</sub>-6 alkyl,

- b) C<sub>3-6</sub> cycloalkyl,
- c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
- d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
- e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
- f) (F)<sub>p</sub>C<sub>1-3</sub> alkyl,
- g) halogen,
- h) OR<sup>4</sup>,
- i) O(CH<sub>2</sub>)<sub>s</sub>OR<sup>4</sup>,
- j) CO<sub>2</sub>R<sup>4</sup>,
- k) (CO)NR<sup>10</sup>R<sup>11</sup>,
- l) O(CO)NR<sup>10</sup>R<sup>11</sup>,
- m) N(R<sup>4</sup>)(CO)NR<sup>10</sup>R<sup>11</sup>,
- n) N(R<sup>10</sup>)(CO)R<sup>11</sup>,
- o) N(R<sup>10</sup>)(CO)OR<sup>11</sup>,
- p) SO<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>,
- q) N(R<sup>10</sup>) SO<sub>2</sub>R<sup>11</sup>,
- r) S(O)<sub>m</sub>R<sup>10</sup>,
- s) CN,
- t) NR<sup>10</sup>R<sup>11</sup>,
- u) N(R<sup>10</sup>)(CO)NR<sup>4</sup>R<sup>11</sup>, and
- v) O(CO)R<sup>4</sup>;

R<sup>4</sup> is selected from: H, C<sub>1-6</sub> alkyl, (F)<sub>p</sub>C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C<sub>1-6</sub> alkoxy;

R<sup>5</sup> is independently selected from H, substituted or unsubstituted C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, aryl, heteroaryl, OR<sup>4</sup>, N(R<sup>4</sup>)<sub>2</sub>, CO<sub>2</sub>R<sup>4</sup> and (F)<sub>p</sub>C<sub>1-6</sub> alkyl;

W is O, NR<sup>4</sup> or C(R<sup>4</sup>)<sub>2</sub>;

X is C or S;

Y is O, (R<sup>4</sup>)<sub>2</sub>, NCN, NSO<sub>2</sub>CH<sub>3</sub> or NCONH<sub>2</sub>, or Y is O<sub>2</sub> when X is S;

R<sup>3</sup> is independently selected from H, substituted or unsubstituted C<sub>1</sub>-C<sub>3</sub> alkyl, CN and CO<sub>2</sub>R<sup>4</sup>;

R<sup>6</sup> is independently selected from H and:

- a) C<sub>1-6</sub> alkyl,
- b) C<sub>3-6</sub> cycloalkyl,
- c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
- d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
- e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R<sup>4</sup>,
- f) (F)<sub>p</sub>C<sub>1-3</sub> alkyl,
- g) halogen,
- h) OR<sup>4</sup>,
- i) O(CH<sub>2</sub>)<sub>5</sub>OR<sup>4</sup>,
- j) CO<sub>2</sub>R<sup>4</sup>,
- k) (CO)NR<sup>10</sup>R<sup>11</sup>,
- l) O(CO)NR<sup>10</sup>R<sup>11</sup>,
- m) N(R<sup>4</sup>)(CO)NR<sup>10</sup>R<sup>11</sup>,
- n) N(R<sup>10</sup>)(CO)R<sup>11</sup>,
- o) N(R<sup>10</sup>)(CO)OR<sup>11</sup>,
- p) SO<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>,
- q) N(R<sup>10</sup>)SO<sub>2</sub>R<sup>11</sup>,
- r) S(O)<sub>m</sub>R<sup>10</sup>,
- s) CN,
- t) NR<sup>10</sup>R<sup>11</sup>,
- u) N(R<sup>10</sup>)(CO)NR<sup>4</sup>R<sup>11</sup>, and
- v) O(CO)R<sup>4</sup>;

$R^{10}$  and  $R^{11}$  are independently selected from: H,  $C_{1-6}$  alkyl,  $(F)_p C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or  $C_{1-6}$  alkoxy, where  $R^{10}$  and  $R^{11}$  may be joined together to form a ring selected from: azetidiny, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from  $R^4$ ;

G-J is selected from: N,  $N-C(R^5)_2$ ,  $C=C(R^5)$ ,  $C=N$ ;  $C(R^5)$ ,  $C(R^5)-C(R^5)_2$ ,  $C(R^5)-C(R^5)_2-C(R^5)_2$ ,  $C=C(R^5)-C(R^5)_2$ ,  $C(R^5)-C(R^5)=C(R^5)$ ,  $C(R^5)-C(R^5)_2-N(R^5)$ ,  $C=C(R^5)-N(R^5)$ ,  $C(R^5)-C(R^5)=N$ ,  $C(R^5)-N(R^5)-C(R^5)_2$ ,  $C=N-C(R^5)_2$ ,  $C(R^5)-N=C(R^5)$ ,  $C(R^5)-N(R^5)-N(R^5)$ ,  $C=N-N(R^5)$ ,  $N-C(R^5)_2-C(R^5)_2$ ,  $N-C(R^5)=C(R^5)$ ,  $N-C(R^5)_2-N(R^5)$ ,  $N-C(R^5)=N$ ,  $N-N(R^5)-C(R^5)_2$  and  $N-N=C(R^5)$ ;

p is 0 to  $2q+1$ , for a substituent with q carbons;


m is 0, 1 or 2;

n is 0 or 1;

s is 1, 2 or 3;


or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

2. (Currently amended) The compound of claim 1 of the formula Ia:



or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

3. (Currently amended) The compound of claim 1 of the formula Ia:




wherein  $R^7$  is phenyl, unsubstituted or substituted with one or substituents independently selected from:

- a)  $C_{1-6}$  alkyl,
- b) OH,
- c)  $OR^5$ ,
- d) halogen,
- e)  $CO_2R^4$ ,
- f)  $S(O)_mR^5$ ,
- g)  $N(R^4)_2$ , and
- j) CN,

or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

4. (Currently amended) The compound of claim 1 of the formula Ia:






wherein  $R^7$  is heteroaryl, unsubstituted or substituted with one or substituents independently selected from:

- a)  $C_{1-6}$  alkyl,
- b) OH,
- c)  $OR^5$ ,
- d) halogen,
- e)  $CO_2R^4$ ,
- f)  $S(O)_mR^5$ ,
- g)  $N(R^4)_2$ , and
- j) CN,

or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

5. (Currently amended) The compound of claim 1 of the formula Ia:




wherein  $R^7$  is selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, unsubstituted or substituted with one or substituents independently selected from:

- a) C<sub>1</sub>-6 alkyl,
- b) C<sub>1</sub>-6 alkoxy,
- c) fluorine,
- d) HO,
- e) OR<sup>5</sup>,
- f) CO<sub>2</sub>R<sup>4</sup>,
- g) CON(R<sup>4</sup>)<sub>2</sub>,
- h) S(O)<sub>m</sub>R<sup>5</sup>, and
- i) N(R<sup>4</sup>)<sub>2</sub>; and

or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

6. (Currently amended) The compound of claim 1 of the formula Ia:




wherein  $R^7$  is heterocycle, unsubstituted or substituted with one or substituents independently selected from:

- a) C<sub>1</sub>-6 alkyl,
- b) C<sub>1</sub>-6 alkoxy,
- c) fluorine,
- d) HO,

- e)  $OR^5$ ,
- f)  $CO_2R^4$ ,
- g)  $CON(R^4)_2$ ,
- h)  $S(O)_mR^5$ , and
- i)  $N(R^4)_2$ ; and

or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~


7. (Currently amended) The compound of claim 1 of the formula Ib:



Ib


or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

8. (Currently amended) The compound of claim 1 of the formula Ic:




or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

9. (Currently amended) The compound of claim 1 of the formula Id:








or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

10. (Currently amended) The compound of claim 1 of the formula:



wherein  $R^1$ ,  $R^2$ ,  $R^{7a}$  and  $R^5$ , and the configuration of C-3, are selected from a single row in the the following table:


C-3	$R^1$	$R^2$	$R^{7a}$	$R^5$
R	CH <sub>3</sub>	H	H	H
S	CH <sub>3</sub>	H	H	H
R	CF <sub>3</sub> CH <sub>2</sub>	H	H	H
R	CF <sub>3</sub> CH <sub>2</sub>	6-Cl	H	H
R	CF <sub>3</sub> CH <sub>2</sub>	7-Cl	H	H
R	CF <sub>3</sub> CH <sub>2</sub>	8-Cl	H	H
R	CF <sub>3</sub> CH <sub>2</sub>	9-Cl	H	H
R,S	<i>n</i> -C <sub>3</sub> H <sub>7</sub>	H	H	H
R,S	<i>i</i> -C <sub>3</sub> H <sub>7</sub>	H	H	H
R,S	<i>n</i> -C <sub>4</sub> H <sub>7</sub>	H	H	H

R	<i>i</i> -C <sub>4</sub> H <sub>7</sub>	H	H	H
S	<i>i</i> -C <sub>4</sub> H <sub>7</sub>	H	H	H
R,S	<i>n</i> -CF <sub>3</sub> (CH <sub>2</sub> ) <sub>3</sub>	H	H	H
R,S	 -CH <sub>2</sub>	H	H	H
R,S		H	H	H
R,S		H	H	H
R,S		H	H	H
R,S		H	H	H
R,S	<i>i</i> -C <sub>3</sub> H <sub>7</sub>	H	2'-F	H
R,S	<i>i</i> -C <sub>3</sub> H <sub>7</sub>	H	2'-F	OH
R,S	<i>i</i> -C <sub>4</sub> H <sub>9</sub>	H	2'-F	H
R,S	<i>i</i> -C <sub>4</sub> H <sub>9</sub>	H	2'-F	OH
R,S	CF <sub>3</sub> CH <sub>2</sub>	H	2'-F	H
R,S	CF <sub>3</sub> CH <sub>2</sub>	H	4'-F	H
R,S	CF <sub>3</sub> CH <sub>2</sub>	H	4'-F	OH

or a pharmaceutically acceptable salt or an individual diastereomer thereof

~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

11. (Currently amended) The compound of claim 1 of the formula:




wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>7</sup> and R<sup>5</sup>, and the configuration of C-3, are selected from a single row in the following table:

C-3	R <sup>1</sup>	R <sup>2</sup>	R <sup>7</sup>	R <sup>5</sup>
R	CH <sub>3</sub>	H	Cyclohexyl	H
R	CF <sub>3</sub> CH <sub>2</sub>	H	<i>i</i> -C <sub>3</sub> H <sub>7</sub>	H
R,S	CH <sub>3</sub>	7- CH <sub>3</sub>	<i>i</i> -C <sub>3</sub> H <sub>7</sub>	H
R,S	CH <sub>3</sub>	8- CH <sub>3</sub>	<i>i</i> -C <sub>3</sub> H <sub>7</sub>	H
S	CF <sub>3</sub> CH <sub>2</sub>	H	<i>t</i> -C <sub>4</sub> H <sub>9</sub>	H

or a pharmaceutically acceptable salt or an individual diastereomer thereof

~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

12. (Currently amended) The compound of claim 1 of the formula:




wherein  $R^1$ ,  $R^2$  and  $Z$ , and the configuration of C-3, are selected from a single row in the following table:

<i>C-3</i>	$R^1$	$R^2$	$Z$
R,S	CH <sub>3</sub>	H	
R,S	CH <sub>3</sub>	7-Cl	
R,S	CF <sub>3</sub> CH <sub>2</sub>	H	
R,S	CF <sub>3</sub> CH <sub>2</sub>	H	



or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

13. (Currently amended) The compound of claim 1 of the formula:





wherein R<sup>1</sup>, R<sup>3</sup> and R<sup>6</sup>, and the configuration of C-3, are selected from a single row in the following table:





C-3	R <sup>1</sup>	R <sup>3</sup>	R <sup>6</sup>
R	CF <sub>3</sub> CH <sub>2</sub>	H	H
R	CF <sub>3</sub> CH <sub>2</sub>	H	5''-CH <sub>3</sub>
R	CF <sub>3</sub> CH <sub>2</sub>	H	6''-F
R	CF <sub>3</sub> CH <sub>2</sub>	CH <sub>3</sub>	H
R	CF <sub>3</sub> CH <sub>2</sub>	H	7''-Cl
R	CF <sub>3</sub> CH <sub>2</sub>	H	6''-CH <sub>3</sub>
R	CF <sub>3</sub> CH <sub>2</sub>	H	6''-CF <sub>3</sub>
R	CF <sub>3</sub> CH <sub>2</sub>	H	6''-F
R	CF <sub>3</sub> CH <sub>2</sub>	H	6''-CO <sub>2</sub> H


R	CF <sub>3</sub> CH <sub>2</sub>	H	6''-CONH <sub>2</sub>
R	CF <sub>3</sub> CH <sub>2</sub>	H	6''-SO <sub>2</sub> CH <sub>3</sub>
R	CF <sub>3</sub> CH <sub>2</sub>	H	5''-CH <sub>3</sub>
R	CF <sub>3</sub> CH <sub>2</sub>	H	5''-Cl
R	CF <sub>3</sub> CH <sub>2</sub>	H	4''-CH <sub>3</sub>
R	CF <sub>3</sub> CH <sub>2</sub>	H	5''-F

or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

14. (Currently amended) A compound selected from:







or a pharmaceutically acceptable salt or an individual diastereomer thereof  
~~and pharmaceutically acceptable salts and individual diastereomers thereof.~~

15. (previously presented)      A pharmaceutical composition which comprises an inert carrier and the compound of Claim 1.

16. (previously presented)      A method for antagonism of CGRP receptor activity in a mammal which comprises the administration of an effective amount of the compound of Claim 1.

17. (previously presented)      A method for treating, controlling, ameliorating or reducing the risk of headache, migraine or cluster headache in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1.

18. (previously presented)      A method of treating or preventing migraine headaches, cluster headaches, and headaches, said method comprising the co-administration, to a person in need of such treatment, of:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from serotonin agonists, analgesics, anti-inflammatory agents, anti-hypertensives and anticonvulsants.

19. (previously presented) The method of claim 18, wherein said second agent is selected from a 5HT<sub>1B/1D</sub> agonist, a 5HT<sub>1D</sub> agonist, and a 5HT<sub>1F</sub> agonist.

20. (previously presented) The method of claim 19, wherein said second agent is selected from rizatriptan, sumatriptan, naratriptan, zolmitriptan, almotriptan, eletriptan, avitriptan, frovatriptan, LY334370 and PNU-142633.

21. (previously presented) The method of claim 18, wherein said second agent is selected from ergotamine and dihydroergotamine.

22. (previously presented) The method of claim 18, wherein said second agent is aspirin or acetaminophen.

23. (previously presented) The method of claim 18, wherein said second agent is a glucocorticoid.

24. (previously presented) The method of claim 18, wherein said second agent is a non-steroidal anti-inflammatory agent.

25. (previously presented) The method of claim 24, wherein said second agent is selected from ibuprofen, ketoprofen, fenoprofen, naproxen, indomethacin, sulindac, meloxicam, piroxicam, tenoxicam, lornoxicam, ketorolac, etodolac, mefenamic acid, meclofenamic acid, flufenamic acid, tolafenamic acid, diclofenac, oxaprozin, apazone, nimesulide, nabumetone, tenidap, etanercept, tolmetin, phenylbutazone, oxyphenbutazone, diflunisal, salsalate, olsalazine and sulfasalazine.

26. (previously presented) The method of claim 18, wherein said second agent is an anticonvulsant selected from topiramate, zonisamide, divalproex sodium, pregabalin, gabapentin, levetiracetam, lamotrigine and tiagabine.

27. (previously presented) The method of claim 18, wherein said second agent is an anti-hypertensive selected from angiotensin II antagonists, angiotensin I antagonists, angiotensin converting enzyme inhibitors, and renin inhibitors.

28. (previously presented) The method of claim 27, wherein said second agent is selected from losartan, candesartan, candesartan cilexetil, irbesartan, valsartan, eprosartan, telmisartan, olmesartan, medoxomil, captopril, benazepril, quinapril, perindopril, ramipril,trandolapril, lisinopril, and enalapril

29. (previously presented) A method of treating or preventing migraine headaches, cluster headaches, and headaches, comprising the co-administration, to a person in need of such treatment, of:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from anti-anxiety agents and neuroleptics.

30. (previously presented) The method of claim 29, wherein said second agent is selected from, diazepam, alprazolam, chlordiazepoxide, olanzapine, droperidol, prochlorperazine, chlorpromazine and quetiapine.

31. (previously presented) A method of treating or preventing migraine headaches, cluster headaches, and headaches, comprising the co-administration, to a person in need of such treatment, of:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from beta-blockers and calcium channel blockers.

32. (previously presented) The method of claim 31, wherein said second agent is selected from timolol, propranolol, atenolol, metoprolol, nadolol, flunarizine, diltiazem, amlodipine,

felodipine, nisolipine, isradipine, nimodipine, lomerizine, verapamil, nifedipine, prochlorperazine and civamide.

33. (previously presented) A method of treating or preventing migraine headaches, cluster headaches, and headaches, comprising the co-administration, to a person in need of such treatment, of:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from anti-depressants, selective serotonin reuptake inhibitors, and NE reuptake inhibitors.

34. (previously presented) The method of claim 33, wherein said second agent is selected from amitriptyline, nortriptyline, clomipramine, imipramine, venlafaxine, doxepin, protriptyline, desipramine, trimipramine, fluoxetine, paroxetine, sertraline, duloxetine, escitalopram, and citalopram.

35. (previously presented) A method of treating or preventing migraine headaches, cluster headaches, and headaches, comprising the co-administration, to a person in need of such treatment, of:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from botulinum toxins A or B.

36. (previously presented) A method of treating or preventing migraine headaches, cluster headaches, and headaches, comprising the co-administration, to a person in need of such treatment, of:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from vanilloid receptor antagonists, adenosine 1 antagonists, NR2B antagonists, substance P antagonists, granzyme B inhibitors, endothelin antagonists, norepinephrin precursors, nitric oxide synthase inhibitors, neuroleptics, bradykinin antagonists, gap junction inhibitors, AMPA/KA antagonists, sigma receptor agonists, chloride channel enhancers, monoamine oxidase inhibitors, opioid agonists, and leukotriene receptor antagonists.

37. (previously presented)      The method of claim 36, wherein said second agent is selected from montelukast and zafirlukast.

38. (previously presented)      The method of claim 36, wherein said second agent is aprepitant.

39. (previously presented)      A method of treating or preventing migraine headaches, cluster headaches, and headaches, comprising the co-administration, to a person in need of such treatment, of:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from the group consisting of anti-emetics, prokinetics, and histamine H1 antagonists.

40. (previously presented)      A pharmaceutical composition comprising:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from serotonin agonists, analgesics, anti-inflammatory agents, and anticonvulsants.



41. (previously presented)      The composition of claim 40, wherein said second agent is selected from a 5HT<sub>1B/1D</sub> agonist, a 5HT<sub>1D</sub> agonist, and a 5HT<sub>1F</sub> agonist.

42. (previously presented)      The composition of claim 41, wherein said second agent is selected from rizatriptan, sumatriptan, naratriptan, zolmitriptan, almotriptan, eletriptan, avitriptan, frovatriptan, LY334370 and PNU-142633.

43. (previously presented)      The composition of claim 40, wherein said second agent is selected from ergotamine and dihydroergotamine.

44. (previously presented)      The composition of claim 40, wherein said second agent is aspirin or acetaminophen.

45. (previously presented)      The composition of claim 40, wherein said second agent is a glucocorticoid.

46. (previously presented)      The composition of claim 40, wherein said second agent is a non-steroidal anti-inflammatory agent.

47. (previously presented)      The composition of claim 46, wherein said second agent is selected from ibuprofen, ketoprofen, fenoprofen, naproxen, indomethacin, sulindac, meloxicam, piroxicam, tenoxicam, lornoxicam, ketorolac, etodolac, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, diclofenac, oxaprozin, apazone, nimesulide, nabumetone, tenidap, etanercept, tolmetin, phenylbutazone, oxyphenbutazone, diflunisal, salsalate, olsalazine and sulfasalazine.

48. (previously presented)      The composition of claim 40, wherein said second agent is an anticonvulsant selected from topiramate, zonisamide, divalproex sodium, pregabalin, gabapentin, levetiracetam, lamotrigine and tiagabine.

49. (previously presented)      A pharmaceutical composition comprising:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from angiotensin II antagonists, angiotensin I antagonists, angiotensin converting enzyme inhibitors, and renin inhibitors.

50. (previously presented)      The composition of claim 49, wherein said second agent is selected from losartan, candesartan, candesartan cilexetil, irbesartan, valsartan, eprosartan, telmisartan, olmesartan, medoxomil, captopril, benazepril, quinapril, perindopril, ramipril, trandolapril, lisinopril, and enalapril.

51. (previously presented)      A pharmaceutical composition comprising:  
  
a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and  
  
a therapeutically effective amount of a second agent selected from anti-anxiety agents and neuroleptics.

52. (previously presented)      The composition of claim 51, wherein said second agent is selected from, diazepam, alprazolam, chlordiazepoxide, olanzapine, droperidol, prochlorperazine, chlorpromazine and quetiapine.

53. (previously presented)      A pharmaceutical composition comprising:  
  
a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and  
  
a therapeutically effective amount of a second agent selected from beta-blockers and calcium channel blockers.

54. (previously presented)      The composition of claim 53, wherein said second agent is selected from timolol, propanolol, atenolol, metoprolol, nadolol, flunarizine, diltiazem, amlodipine,

felodipine, nisolipine, isradipine, nimodipine, lomerizine, verapamil, nifedipine, prochlorperazine and civamide.

55. (previously presented) A pharmaceutical composition comprising:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from anti-depressants, selective serotonin reuptake inhibitors, and NE reuptake inhibitors.

56. (previously presented) The composition of claim 55, wherein said second agent is selected from amitriptyline, nortriptyline, clomipramine, imipramine, venlafaxine, doxepin, protriptyline, desipramine, trimipramine, fluoxetine, paroxetine, sertraline, duloxetine, escitalopram, and citalopram.

57. (previously presented) A pharmaceutical composition comprising:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from botulinum toxins A or B.

58. (previously presented) A pharmaceutical composition comprising:

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a therapeutically effective amount of a second agent selected from vanilloid receptor antagonists, adenosine 1 antagonists, NR2B antagonists, substance P antagonists, granzyme B inhibitors, endothelin antagonists, norepinephrin precursors, nitric oxide synthase inhibitors, neuroleptics, bradykinin antagonists, gap junction inhibitors, AMPA/KA antagonists, sigma receptor agonists, chloride channel enhancers, monoamine oxidase inhibitors, opioid agonists, and leukotriene receptor antagonists.

59. (previously presented)      The composition of claim 58, wherein said second agent is selected from montelukast and zafirlukast.

60. (previously presented)      The composition of claim 58, wherein said second agent is aprepitant.

61. (previously presented)      A pharmaceutical composition comprising:  
  
a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and  
  
a therapeutically effective amount of a second agent selected from the group consisting of anti-emetics, prokinetics, and histamine H1 antagonists.